Poxel S.A. (LON:0RA2)

Market Cap	9.27M -64.4%
Revenue (ttm)	6.56M +250.0%
Net Income	-11.71M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,177
Open	0.20155
Previous Close	0.20255
Day's Range	0.2005 - 0.2020
52-Week Range	0.1892 - 0.4900
Beta	1.28
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RA2

Financial Performance

In 2024, Poxel's revenue was 6.64 million, an increase of 234.98% compared to the previous year's 1.98 million. Losses were -18.31 million, -47.83% less than in 2023.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error